标题
Cell Cycle Regulation and Melanoma
作者
关键词
Metastatic melanoma, Cell cycle regulation, CDK4/6 inhibitors, G1-S checkpoint, G2-M checkpoint, WEE1, Chk1, MK2, Anti-mitotic agents
出版物
Current Oncology Reports
Volume 18, Issue 6, Pages -
出版商
Springer Nature
发表日期
2016-04-22
DOI
10.1007/s11912-016-0524-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
- (2015) Gry Irene Magnussen et al. BMC CANCER
- Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models
- (2015) Y. Liu et al. CLINICAL CANCER RESEARCH
- Cell cycle control as a promising target in melanoma
- (2015) Belinda Lee et al. CURRENT OPINION IN ONCOLOGY
- Will Targeting Chk1 Have a Role in the Future of Cancer Therapy?
- (2015) Nandini Sakurikar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
- (2015) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
- (2015) Khanh Do et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma
- (2015) Christian Posch et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy
- (2015) Letizia Porcelli et al. Journal of Translational Medicine
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Abstract PR06: Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors
- (2015) Ryan J. Sullivan et al. MOLECULAR CANCER THERAPEUTICS
- The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression
- (2015) M. S. Phadke et al. MOLECULAR CANCER THERAPEUTICS
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- The Genetic Evolution of Melanoma from Precursor Lesions
- (2015) A. Hunter Shain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aurora Kinase Inhibitors: Current Status and Outlook
- (2015) Vassilios Bavetsias et al. Frontiers in Oncology
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
- (2014) Edward Sausville et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells
- (2014) A. E. Vilgelm et al. CANCER RESEARCH
- Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
- (2014) K. G. Griewank et al. JNCI-Journal of the National Cancer Institute
- The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
- (2014) V. Yadav et al. MOLECULAR CANCER THERAPEUTICS
- Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
- (2014) Richard J. Young et al. Pigment Cell & Melanoma Research
- The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design
- (2013) Ruth Thompson et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
- (2013) K. L. Nathanson et al. CLINICAL CANCER RESEARCH
- The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
- (2013) K. E. Sheppard et al. CLINICAL CANCER RESEARCH
- A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
- (2013) John J Nemunaitis et al. Journal of Translational Medicine
- The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines
- (2013) Lifang Xie et al. MELANOMA RESEARCH
- Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response
- (2013) H. Christian Reinhardt et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- p16INK4adeficiency promotes DNA hyper-replication and genetic instability in melanocytes
- (2013) Carina Fung et al. Pigment Cell & Melanoma Research
- Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
- (2012) Jeffry L. Dean et al. CELL CYCLE
- CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
- (2012) A. Kathleen McClendon et al. CELL CYCLE
- Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo
- (2012) Laura Carrassa et al. CELL CYCLE
- Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale
- (2012) E. Komlodi-Pasztor et al. CLINICAL CANCER RESEARCH
- Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence
- (2012) Yan Liu et al. EMBO Molecular Medicine
- Aurora B Is Regulated by the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (MAPK/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma Cells
- (2012) Caroline Bonet et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
- (2012) Patrick J. Roberts et al. JNCI-Journal of the National Cancer Institute
- Abstract B234: LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts.
- (2012) C. Sanchez-Martinez et al. MOLECULAR CANCER THERAPEUTICS
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
- (2012) Lawrence N Kwong et al. NATURE MEDICINE
- A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress
- (2012) K Brooks et al. ONCOGENE
- High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy
- (2012) Gry Irene Magnussen et al. PLoS One
- Mitosis-targeted anti-cancer therapies: where they stand
- (2012) K-S Chan et al. Cell Death & Disease
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- (2011) G K Schwartz et al. BRITISH JOURNAL OF CANCER
- NRAS mutation status is an independent prognostic factor in metastatic melanoma
- (2011) John A. Jakob et al. CANCER
- Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation
- (2011) Kurtis D. Davies et al. CANCER BIOLOGY & THERAPY
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
- (2011) Gottfried E. Konecny et al. CLINICAL CANCER RESEARCH
- Checkpoint kinase inhibitors: a patent review (2009 – 2010)
- (2011) Michael Lainchbury et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
- (2011) F Xing et al. ONCOGENE
- Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
- (2010) K. Michaud et al. CANCER RESEARCH
- Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
- (2010) Christophe Le Tourneau et al. EUROPEAN JOURNAL OF CANCER
- Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
- (2010) J L Dean et al. ONCOGENE
- Reduced p16 and Increased Cyclin D1 and pRb Expression Are Correlated With Progression in Cutaneous Melanocytic Tumors
- (2009) Rooshdiya Z. Karim et al. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
- The decision to enter mitosis: feedback and redundancy in the mitotic entry network
- (2009) Arne Lindqvist et al. JOURNAL OF CELL BIOLOGY
- Targeted Depletion of Polo-Like Kinase (Plk) 1 Through Lentiviral shRNA or a Small-Molecule Inhibitor Causes Mitotic Catastrophe and Induction of Apoptosis in Human Melanoma Cells
- (2009) Travis L. Schmit et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started